ClinicalTrials.gg
RecruitingNCT06531486Updated Oct 26, 2026

A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors

A Phase 1 interventional study of XS-02 capsules in Solid Tumor, Ovarian Cancer and Breast Cancer, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionnone(registry's first term: Ovarian Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Ovarian Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 26, 2026Now RecruitingFirst site in China+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.

Read the detailed description

This is a multicenter, open label, single-arm Phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic profile, and initial efficacy of XS-02 capsules in patients with advanced solid tumors.

02

Conditions studied

  • Solid Tumor
  • Ovarian Cancer
  • Breast Cancer
  • Endometrial Cancer
  • Osteosarcoma

Browse trials for

Keywords

  • XS-02
  • Cell cycle checkpoint kinase 1(CHK1)
  • Solid tumor
  • ovarian cancer
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 37 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients must meet all of the following criteria for admission:

  1. Volunteer to participate in clinical trials and sign an form (ICF).
  2. Age ≥18 years old, ≤75 years old, regardless of gender.
  3. Phase Ia: patients with or cytologically confirmed locally advanced or solid tumors for whom no standard therapy is available, who have failed standard therapy, or who are intolerant of standard therapy. In the Phase Ib dose-expansion stage, Cohort A will enroll patients with advanced serous endometrial cancer who have failed prior standard therapy, and Cohort B will enroll patients with osteosarcoma who have failed prior standard therapy or are intolerant of standard therapy..
  4. The phase Ia dose escalation has at least one evaluable lesion; in the phase Ib dose expansion has at least one (based on V1.1). For patients who have previously received radiation therapy, a radiation-treated lesion may be considered a target lesion if the lesion can be measured according to RECIST V1.1 and there is objective evidence of significant progression after radiation therapy.
  5. All participants enrolled in phase Ib must provide a sufficient quantity of tumor tissue samples and control blood samples for predictive biomarker analysis.

6: The (ECOG) scored 0-1, with no deterioration within 2 weeks prior to the first dose. Osteosarcoma patients with an ECOG score of 2 due to functional impairment caused by prior surgical resection or due to the anatomical location of the tumor might be enrolled at the investigator's discretion.

7:The expected survival time is ≥3 months. 8:Routine blood tests before first dosing must be within the following range (no blood transfusion or use of drugs that assist in raising white blood cells, , , such as cytokines or erythropoietin, etc., for at least 7 days prior to first dosing) a. Hemoglobin (HB) ≥90 g/L. b. Platelet (PLT) count ≥100×10\^9/L. c. Absolute count of neutrophils (ANC) ≥1.5×10\^9/L.

9:Has proper organ function 10:Female subjects of reproductive age in the screening period had negative serological pregnancy test results within 7 days prior to the first dosing. The subjects also agreed to use a reliable method of for 3 months from signing the informed consent to the last dosing. Including but not limited to: forbidden Sex, male vasectomy, female sterilization, effective IUD, condoms, effective contraceptive drugs.

11:Patients were able to comply with the visits required by the study procedure and protocol.

Patients who meet any of the following conditions are not allowed to enter this clinical study:

  1. Chemotherapy, small molecule targeted therapy, endocrine therapy and traditional Chinese medicine with anti-tumor indications were received within 2 weeks prior to the first dose. Received tumor immunotherapy, antibodies, polypeptide antitumor, or other drugs within 4 weeks prior to initial administration.
  2. Patients who had undergone therapeutic surgery other than diagnosis, , drainage, or radical radiotherapy within 4 weeks prior to initial dosing, or who expected to undergo major surgery during the study period. Had received palliative radiotherapy within 2 weeks prior to the first dose, or had used radiopharma (strontium, samarium, etc.) within 56 days prior to the first dose.
  3. The toxicity of previous antitumor therapy has not recovered (> 5.0 grade 1),alopecia, pigmentation, or other toxicity that the investigators assessed had become chronic and did not affect the safety of the investigational medication returned to NCI-CTCAE 5.0 level 2 or below.

4:Imaging (CT or MRI) shows that the tumor has invaded large blood vessels (such as aorta, pulmonary artery, pulmonary vein, vena cava, etc.) or is at risk of bleeding (such as esophageal and gastric varices) or fistula.

5: Osteosarcoma patients with severe tumor-induced bone injury that has occurred or may occur after enrollment, such as pathologic fractures of weight-bearing bones or spinal cord compression that have occurred within 3 months or may occur after enrollment; or uncontrolled pain related to bone metastases.

6: Inflammatory breast cancer 7: There is clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage or medical intervention (within 2 weeks prior to administration).

8: Patients with central nervous system metastasis who meet any of the following conditions: a. need to undergo local treatment (surgery, radiation or other); b. Patients who require hormones, anticonvulsants, or other dehydration treatment; c. Meningeal, midbrain, pontine, bulbar, or spinal cord metastases. Only patients with BMS who were asymptomatic, stable on imaging assessment (no significant progression of on imaging assessment within the first 4 weeks of enrollment) and did not require treatment were admitted. d. Presence of spinal cord compression, or brain or CNS injury.

9: Patients with difficulty swallowing, or a history of severe gastrointestinal disease (e.g. active inflammatory bowel disease, gastrointestinal perforation) and related symptoms that cannot be reasonably controlled; Or have a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, intestinal obstruction, short bowel syndrome) or other malabsorption conditions that affect drug absorption.

10: Have active or unstable cardiovascular disease 11: Bacterial, fungal, or viral infections requiring intravenous antibiotics/antivirals or hospitalization were investigated within 2 weeks prior to initial drug administration.

12: People who have a history of prior severe allergies or are allergic to any active or inactive ingredient of the investigatory drug.

13: Known acute or active (HBV surface antigen positive with HBV DNA≥500 IU/mL), virus infection (HCV RNA exceeding the normal range), syphilis infection, and (HIV) infection.

14: Other primary have been diagnosed within the previous five years (the following conditions can be included: cured and completely resected basal and squamous cell skin cancers, completely resected cancers of any type in situ).

15: Use within 2 weeks prior to first administration or expect to use a booster or strong inducer during study drug administration.

16: Use within 2 weeks prior to first administration, or expect to use any drug known to prolong the during study drug administration.

17: The ATR/CHK1 pathway has been treated in the past. 18: Had a bone marrow transplant or had extensive radiation therapy on more than 25% of the bone marrow in the 8 weeks prior to initial dosing.

19: A history of blood clotting disorders; Anticoagulant or antiplatelet therapy (oral aspirin dose ≤100 mg/d and subcutaneous injection of low molecular weight heparin for prevention of deep vein thrombosis) is required.

20: Pregnant and lactating women. 21: According to the judgment of the investigator, any other serious or uncontrolled acute or chronic medical or psychiatric condition, or abnormal laboratory tests or other reasons are not suitable for participation in this clinical study.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Phase I dose escalation and dose expansion

    Experimental: XS-02 Dosage form:capsule Specification: 5mg,25mg Dose: Phase I dose escalation, orally, once daily, the administration schedule (including dose,administration frequency/interval, administration cycle, etc.) can be adjusted according to the experimental data. Phase II Dose Expansion/Optimal Dose selection, will be determined based on the Phase I dose escalation results. Method of administration: Oral

    Drug: XS-02 capsules

Interventions

  • DrugXS-02 capsules

    Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.

06

What researchers measure

Primary outcomes

  1. Occurrence of Dose Limiting Toxicity (DLT) (DLT observation period).(phase Ia)

    DLT is defined as a dose-limiting toxic event that occurs during DLT observation.

    Time frame: from first dose up to 31 days

  2. Maximum tolerance dose (MTD) and/or clinical Phase II promoter dose(RP2D).(phase Ia)

    MTD is defined as the maximum tolerated dose。RP2D is defined as the recommended dose for Phase II clinical studies

    Time frame: from first dose to phase Ia completion

  3. Objective Response Rate(ORR)(phase Ib)

    ORR is defined as the proportion of patients with confirmed Complete Response (CR) or Partial Response (PR) as evaluated according to RECIST version 1.1.

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. Other safety endpoints(phase Ia/Ib)

    According to National Cancer Institute Common Terminology Criteria for Adverse Events(NCI-CTCAE) version 5.0 evaluates the incidence and severity of adverse events, serious adverse events, deaths, and safety screening abnormalities (such as laboratory tests, vital signs, physical examinations, electrocardiograms, ECOG, etc.). Proportion of patients undergoing dose adjustment or discontinuation due to drug toxicity.

    Time frame: From enrollment up to 30 days after last dose

  2. PK parameters(phase Ia/Ib)

    Area under the concentration-time curve from time 0 (pre-dose) to the last measurable time of concentration(AUC0-t)

    Time frame: up to 20weeks

  3. PK parameters(phase Ia/Ib)

    Area under the concentration-time curve from time 0 (pre-dose) to infinity(AUC0-∞)

    Time frame: up to 20weeks

  4. PK parameters(phase Ia/Ib)

    Area under the plasma drug concentration-time curve over a dosing interval at steady state(AUCtau)

    Time frame: up to 20weeks

  5. PK parameters(phase Ia/Ib)

    Maximum plasma concentration(Cmax)

    Time frame: up to 20weeks

  6. PK parameters(phase Ia/Ib)

    Time to maximum plasma concentration(Tmax)

    Time frame: up to 20weeks

  7. PK parameters(phase Ia/Ib)

    half-life(t1/2)

    Time frame: up to 20weeks

  8. DCR(phase Ia/Ib)

    DCR is defined as the proportion of patients with confirmed Complete Response(CR), Partial Response(PR), and Stable Disease(SD) based on the Response Evaluation Criteria in Solid Tumors Version 1.1(RECISIT V1.1) evaluation.

    Time frame: Through study completion, an average of 3 years

  9. CBR(phase Ia/Ib)

    CBR was defined as the proportion of patients with CR, PR, and SD lasting at least 24 weeks, as evaluated according to RECIST version 1.1.

    Time frame: Through study completion, an average of 3 years

  10. DOR(phase Ia/Ib)

    DOR is defined as the time from the date of first documented response (which is subsequently confirmed) until progression per RECIST V1.1 criteria or death due to any cause

    Time frame: Through study completion, an average of 3 years

  11. TTR(phase Ia/Ib)

    TTR is defined as the time from the first dose to the first confirmed PR or CR evaluated according to RECIST version 1.1.

    Time frame: Through study completion, an average of 3 years

  12. PFS(phase Ia/Ib)

    PFS is defined as the time until disease progression or death of the first dose, whichever occurs first.

    Time frame: Through study completion, an average of 3 years

  13. OS(phase Ia/Ib)

    OS is defined as the time from the first use of the study drug until death from any cause.

    Time frame: Through study completion, an average of 3 years

  14. ORR(phase Ia)

    ORR is defined as the proportion of patients with confirmed Complete Response (CR) or Partial Response (PR) as evaluated according to RECIST version 1.1.

    Time frame: from first dose to phase Ia completion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2024 (actual). Primary completion is estimated for May 2029, 57 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jul 2024 → Aug 2024, primary completion Feb 2027 → May 2029 and completion Aug 2027 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Aug 1, 2024
StartActual
Aug 15, 2024was Jul 2024
Primary completionEst.
May 15, 2029was Feb 2027
CompletionEst.
Nov 13, 2029was Aug 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added — first site in China
Show site
  • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
Oct 26, 2026
Start date
Jul 29, 2024→Aug 15, 2024 (actual)
Oct 26, 2026
Primary completion
Feb 28, 2027→May 15, 2029
Oct 26, 2026
Study completion
Aug 30, 2027→Nov 13, 2029
Oct 26, 2026
Eligibility
10 inclusion criteria removed; 7 exclusion criteria removed; 18 criteria edited, 5 added
What changed in the criteria
  • AddedPatients must meet all of the following criteria for admission:
  • ChangedBefore Patients with locally advanced or metastatic solid tumors diagnosed histologically or cytologically have no standard treatment options or have failed standard treatment or are unable to tolerate standard treatment. Phase II dose expansion/Optimal dose selection phase enrolls advanced ovarian cancer and other advanced entities a tumor patient.Now Phase Ia: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors for whom no standard therapy is available, who have failed standard therapy, or who are intolerant of standard therapy. In the Phase Ib dose-expansion stage, Cohort A will enroll patients with advanced serous endometrial cancer who have failed prior standard therapy, and Cohort B will enroll patients with osteosarcoma who have failed prior standard therapy or are intolerant of standard therapy..
  • EditedThe phase IIa dose escalation phase has at least one evaluable lesion and; in the phase IIIb dose expansion/optimal dose selection phase has at least one measurable lesion (based on RECIST V1.1). For patients who have previously received radiation therapy, a radiation-treated lesion may be considered a target lesion if the lesion can be measured according to RECIST V1.1 and there is objective evidence of significant progression after radiation therapy.
  • AddedAll participants enrolled in phase Ib must provide a sufficient quantity of tumor tissue samples and control blood samples for predictive biomarker analysis.
  • Added6: The Eastern Cooperative Oncology Group (ECOG) scored 0-1, with no deterioration within 2 weeks prior to the first dose. Osteosarcoma patients with an ECOG score of 2 due to functional impairment caused by prior surgical resection or due to the anatomical location of the tumor might be enrolled at the investigator's discretion.
  • Edited7:The expected survival time is ≥3 months. 8:Routine blood tests before first dosing must be within the following range (no blood transfusion or use of drugs that assist in raising white blood cells, platelets, hemoglobin, such as cytokines or erythropoietin, etc., for at least 7 days prior to first dosing) a. Hemoglobin (HB) ≥90 g/L. b. Platelet (PLT) count ≥100×10\^9/L. c. Absolute count of neutrophils (ANC) ≥1.5×10\^9/L.
  • Edited9:Has proper organ function 10:Female subjects of reproductive age in the screening period had negative serological pregnancy test results within 7 days prior to the first dosing. The subjects also agreed to use a reliable method of contraception for 3 months from signing the informed consent to the last dosing. Including but not limited to: forbidden Sex, male vasectomy, female sterilization, effective IUD, condoms, effective contraceptive drugs.
  • Edited11:Patients were able to comply with the visits required by the study procedure and protocol.
  • EditedPatients with central nervous system metastasis who meet any of the following conditions are not allowed to enter this clinical study:
  • Edited4:Imaging (Computed Tomography(CT) or magnetic resonance imaging(MRI)) shows that the tumor has invaded large blood vessels (such as aorta, pulmonary artery, pulmonary vein, vena cava, etc.) or is at risk of bleeding (such as esophageal and gastric varices) or fistula.
  • Added5: Osteosarcoma patients with severe tumor-induced bone injury that has occurred or may occur after enrollment, such as pathologic fractures of weight-bearing bones or spinal cord compression that have occurred within 3 months or may occur after enrollment; or uncontrolled pain related to bone metastases.
  • Edited6: Inflammatory breast cancer 7: There is clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage or medical intervention (within 2 weeks prior to administration).
  • Added8: Patients with central nervous system metastasis who meet any of the following conditions: a. need to undergo local treatment (surgery, radiation or other); b. Patients who require steroid hormones, anticonvulsants, or other dehydration treatment; c. Meningeal, midbrain, pontine, bulbar, or spinal cord metastases. Only patients with BMS who were asymptomatic, stable on imaging assessment (no significant progression of brain metastases on imaging assessment within the first 4 weeks of enrollment) and did not require treatment were admitted. d. Presence of spinal cord compression, or brain or CNS injury.
  • Edited9: Patients with difficulty swallowing, or a history of severe gastrointestinal disease (e.g. active inflammatory bowel disease, gastrointestinal perforation) and related symptoms that cannot be reasonably controlled; Or have a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, intestinal obstruction, short bowel syndrome) or other malabsorption conditions that affect drug absorption.
  • Edited10: Have active or unstable cardiovascular disease 11: Bacterial, fungal, or viral infections requiring intravenous antibiotics/antivirals or hospitalization were investigated within 2 weeks prior to initial drug administration.
  • Edited12: People who have a history of prior severe allergies, or are allergic to any active or inactive ingredient of the investigatory drug.
  • Edited13: Known acute or active hepatitis B (hepatitis B virus(HBV) surface antigen positive with HBV deoxyribonucleic acid(DNA)≥500 IU/mL), hepatitis C virus infection (HCV Ribonucleic Acid(RNA) exceeding the normal range), syphilis infection, and human immunodeficiency virus (HIV) infection.
  • Edited14: Other primary malignancies have been diagnosed within the previous five years (the following conditions can be included: cured and completely resected basal and squamous cell skin cancers, completely resected cancers of any type in situ).
  • Edited15: Use within 2 weeks prior to first administration, or expect to use a Cytochrome P450 enzyme(CYP3A) booster or strong inducer during study drug administration.
  • Edited16: Use within 2 weeks prior to first administration, or expect to use any drug known to prolong the corrected QT(QTc) interval during study drug administration.
  • Edited17: The ATR/CHK1 pathway has been treated in the past. 18: Had a bone marrow transplant or had extensive radiation therapy on more than 25% of the bone marrow in the 8 weeks prior to initial dosing.
  • Edited19: A history of blood clotting disorders; Anticoagulant or antiplatelet therapy (oral aspirin dose ≤100 mg/d and subcutaneous injection of low molecular weight heparin for prevention of deep vein thrombosis) is required.
  • Edited20: Pregnant and lactating women. 21: According to the judgment of the investigator, any other serious or uncontrolled acute or chronic diseasesmedical or psychiatric condition, or abnormal laboratory tests or other reasons are not suitable for participation in this clinical study.
Inclusion criteria
  • RemovedThe Eastern Cooperative Oncology Group (ECOG) scored 0-1.
  • RemovedThe expected survival time is ≥3 months.
  • RemovedHemoglobin (HB) ≥90 g/L.
  • RemovedPlatelet (PLT) count ≥100×109/L or ≥5.6 mmol/L.
  • RemovedAbsolute count of neutrophils (ANC) ≥1.5×109/L.
  • RemovedHas proper organ function
  • RemovedAdmission criteria specific to Stage II dose expansion/Optimal dose Selection stage ovarian cancer:
  • RemovedHistologically confirmed and documented advanced recurrent epithelial ovarian cancer (high-grade serous ovarian cancer), fallopian tube cancer, and primary peritoneal cancer.
  • RemovedFor platinum-resistant diseases, there must be evidence of disease progression within 6 months of the most recent platinum-containing treatment, calculated from the date of the last platinum treatment dose. Platinum-refractory patients were not admitted (platinum-refractory was defined as during or after chemotherapy containing platinum-containing chemotherapy)Progress within 4 weeks.
  • RemovedHave previously received at least 1 standard line of treatment.
Exclusion criteria
  • Removedneed to undergo local treatment (surgery, radiation or other);
  • RemovedPatients who require steroid hormones, anticonvulsants, or other dehydration treatment;
  • RemovedOnly enrollment is allowed Stable symptoms, imaging assessment (imaging evaluation of brain metastases within 4 weeks prior to enrollmentlesions that have not progressed) and do not require treatment
  • Removedinflammatory breast cancer
  • RemovedHave active or unstable cardiovascular disease
  • RemovedThe ATR/CHK1 pathway has been treated in the past.
  • RemovedPregnant and lactating women.
Oct 26, 2026
Interventions
Added Drug: XS-02 capsules; removed XS-02 capsules. Arm changed Phase I dose escalation/Phase II dose expansion→Phase I dose escalation and dose expansion
Oct 26, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedOccurrence of Dose Limiting Toxicity (DLT) (DLT observation period).(phase IIa)Time frame: from first dose up to 31 days
  • EditedMaximum toleratedtolerance dose (MTD) and/or Recommendedclinical Phase II Dosepromoter dose(RP2D).(phase IIa)Time frame: Time Frame: from first dose to phase I completion, an average of 1.5 years → from first dose to phase Ia completion
  • EditedObjective Response Rate(ORR)(phase IIIb)Time frame: Through study completion, an average of 3 years
Oct 26, 2026
Secondary outcomes
14 edited
What changed in the outcomes
  • EditedPharmacokinetics(PK) parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
  • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
  • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
  • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
  • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
  • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
  • EditedDisease Control Rate(DCR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
  • Edited(Clinical Benefit Rate(CBR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
  • EditedDuration of Response(DOR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
  • EditedTime to Response(TTR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
  • EditedProgression Free Survival(PFS)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
  • EditedOverall Survival(OS)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
  • EditedObjective Response Rate(ORR)(phase IIa)Time frame: from first dose to phase I completion, an average of 1.5 years → from first dose to phase Ia completion
  • ChangedBefore the incidence and severity of adverse events, serious adverse events, deaths, and safety screening abnormalities(phase I/II)Now Other safety endpoints(phase Ia/Ib)Time frame: From enrollment up to 30 days after last dose
Oct 26, 2026
Title
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
Oct 26, 2026
Sponsor
NovaOnco Therapeutics Co., Ltd.→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Oct 26, 2026
Design
Removed Phase 2
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Cancer Hospital Chinese Academy of Medical Sciences · Beijing, China
    Start date Jul 29, 2024→Aug 15, 2024 (now actual)
    Primary completion Feb 28, 2027→May 15, 2029
    Study completion Aug 30, 2027→Nov 13, 2029
    Eligibility 10 inclusion criteria removed; 7 exclusion criteria removed; 18 criteria edited, 5 added
    What changed in the criteria
    • AddedPatients must meet all of the following criteria for admission:
    • ChangedBefore Patients with locally advanced or metastatic solid tumors diagnosed histologically or cytologically have no standard treatment options or have failed standard treatment or are unable to tolerate standard treatment. Phase II dose expansion/Optimal dose selection phase enrolls advanced ovarian cancer and other advanced entities a tumor patient.Now Phase Ia: patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors for whom no standard therapy is available, who have failed standard therapy, or who are intolerant of standard therapy. In the Phase Ib dose-expansion stage, Cohort A will enroll patients with advanced serous endometrial cancer who have failed prior standard therapy, and Cohort B will enroll patients with osteosarcoma who have failed prior standard therapy or are intolerant of standard therapy..
    • EditedThe phase IIa dose escalation phase has at least one evaluable lesion and; in the phase IIIb dose expansion/optimal dose selection phase has at least one measurable lesion (based on RECIST V1.1). For patients who have previously received radiation therapy, a radiation-treated lesion may be considered a target lesion if the lesion can be measured according to RECIST V1.1 and there is objective evidence of significant progression after radiation therapy.
    • AddedAll participants enrolled in phase Ib must provide a sufficient quantity of tumor tissue samples and control blood samples for predictive biomarker analysis.
    • Added6: The Eastern Cooperative Oncology Group (ECOG) scored 0-1, with no deterioration within 2 weeks prior to the first dose. Osteosarcoma patients with an ECOG score of 2 due to functional impairment caused by prior surgical resection or due to the anatomical location of the tumor might be enrolled at the investigator's discretion.
    • Edited7:The expected survival time is ≥3 months. 8:Routine blood tests before first dosing must be within the following range (no blood transfusion or use of drugs that assist in raising white blood cells, platelets, hemoglobin, such as cytokines or erythropoietin, etc., for at least 7 days prior to first dosing) a. Hemoglobin (HB) ≥90 g/L. b. Platelet (PLT) count ≥100×10\^9/L. c. Absolute count of neutrophils (ANC) ≥1.5×10\^9/L.
    • Edited9:Has proper organ function 10:Female subjects of reproductive age in the screening period had negative serological pregnancy test results within 7 days prior to the first dosing. The subjects also agreed to use a reliable method of contraception for 3 months from signing the informed consent to the last dosing. Including but not limited to: forbidden Sex, male vasectomy, female sterilization, effective IUD, condoms, effective contraceptive drugs.
    • Edited11:Patients were able to comply with the visits required by the study procedure and protocol.
    • EditedPatients with central nervous system metastasis who meet any of the following conditions are not allowed to enter this clinical study:
    • Edited4:Imaging (Computed Tomography(CT) or magnetic resonance imaging(MRI)) shows that the tumor has invaded large blood vessels (such as aorta, pulmonary artery, pulmonary vein, vena cava, etc.) or is at risk of bleeding (such as esophageal and gastric varices) or fistula.
    • Added5: Osteosarcoma patients with severe tumor-induced bone injury that has occurred or may occur after enrollment, such as pathologic fractures of weight-bearing bones or spinal cord compression that have occurred within 3 months or may occur after enrollment; or uncontrolled pain related to bone metastases.
    • Edited6: Inflammatory breast cancer 7: There is clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage or medical intervention (within 2 weeks prior to administration).
    • Added8: Patients with central nervous system metastasis who meet any of the following conditions: a. need to undergo local treatment (surgery, radiation or other); b. Patients who require steroid hormones, anticonvulsants, or other dehydration treatment; c. Meningeal, midbrain, pontine, bulbar, or spinal cord metastases. Only patients with BMS who were asymptomatic, stable on imaging assessment (no significant progression of brain metastases on imaging assessment within the first 4 weeks of enrollment) and did not require treatment were admitted. d. Presence of spinal cord compression, or brain or CNS injury.
    • Edited9: Patients with difficulty swallowing, or a history of severe gastrointestinal disease (e.g. active inflammatory bowel disease, gastrointestinal perforation) and related symptoms that cannot be reasonably controlled; Or have a gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, intestinal obstruction, short bowel syndrome) or other malabsorption conditions that affect drug absorption.
    • Edited10: Have active or unstable cardiovascular disease 11: Bacterial, fungal, or viral infections requiring intravenous antibiotics/antivirals or hospitalization were investigated within 2 weeks prior to initial drug administration.
    • Edited12: People who have a history of prior severe allergies, or are allergic to any active or inactive ingredient of the investigatory drug.
    • Edited13: Known acute or active hepatitis B (hepatitis B virus(HBV) surface antigen positive with HBV deoxyribonucleic acid(DNA)≥500 IU/mL), hepatitis C virus infection (HCV Ribonucleic Acid(RNA) exceeding the normal range), syphilis infection, and human immunodeficiency virus (HIV) infection.
    • Edited14: Other primary malignancies have been diagnosed within the previous five years (the following conditions can be included: cured and completely resected basal and squamous cell skin cancers, completely resected cancers of any type in situ).
    • Edited15: Use within 2 weeks prior to first administration, or expect to use a Cytochrome P450 enzyme(CYP3A) booster or strong inducer during study drug administration.
    • Edited16: Use within 2 weeks prior to first administration, or expect to use any drug known to prolong the corrected QT(QTc) interval during study drug administration.
    • Edited17: The ATR/CHK1 pathway has been treated in the past. 18: Had a bone marrow transplant or had extensive radiation therapy on more than 25% of the bone marrow in the 8 weeks prior to initial dosing.
    • Edited19: A history of blood clotting disorders; Anticoagulant or antiplatelet therapy (oral aspirin dose ≤100 mg/d and subcutaneous injection of low molecular weight heparin for prevention of deep vein thrombosis) is required.
    • Edited20: Pregnant and lactating women. 21: According to the judgment of the investigator, any other serious or uncontrolled acute or chronic diseasesmedical or psychiatric condition, or abnormal laboratory tests or other reasons are not suitable for participation in this clinical study.
    Inclusion criteria
    • RemovedThe Eastern Cooperative Oncology Group (ECOG) scored 0-1.
    • RemovedThe expected survival time is ≥3 months.
    • RemovedHemoglobin (HB) ≥90 g/L.
    • RemovedPlatelet (PLT) count ≥100×109/L or ≥5.6 mmol/L.
    • RemovedAbsolute count of neutrophils (ANC) ≥1.5×109/L.
    • RemovedHas proper organ function
    • RemovedAdmission criteria specific to Stage II dose expansion/Optimal dose Selection stage ovarian cancer:
    • RemovedHistologically confirmed and documented advanced recurrent epithelial ovarian cancer (high-grade serous ovarian cancer), fallopian tube cancer, and primary peritoneal cancer.
    • RemovedFor platinum-resistant diseases, there must be evidence of disease progression within 6 months of the most recent platinum-containing treatment, calculated from the date of the last platinum treatment dose. Platinum-refractory patients were not admitted (platinum-refractory was defined as during or after chemotherapy containing platinum-containing chemotherapy)Progress within 4 weeks.
    • RemovedHave previously received at least 1 standard line of treatment.
    Exclusion criteria
    • Removedneed to undergo local treatment (surgery, radiation or other);
    • RemovedPatients who require steroid hormones, anticonvulsants, or other dehydration treatment;
    • RemovedOnly enrollment is allowed Stable symptoms, imaging assessment (imaging evaluation of brain metastases within 4 weeks prior to enrollmentlesions that have not progressed) and do not require treatment
    • Removedinflammatory breast cancer
    • RemovedHave active or unstable cardiovascular disease
    • RemovedThe ATR/CHK1 pathway has been treated in the past.
    • RemovedPregnant and lactating women.
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedOccurrence of Dose Limiting Toxicity (DLT) (DLT observation period).(phase IIa)Time frame: from first dose up to 31 days
    • EditedMaximum toleratedtolerance dose (MTD) and/or Recommendedclinical Phase II Dosepromoter dose(RP2D).(phase IIa)Time frame: Time Frame: from first dose to phase I completion, an average of 1.5 years → from first dose to phase Ia completion
    • EditedObjective Response Rate(ORR)(phase IIIb)Time frame: Through study completion, an average of 3 years
    Secondary outcomes 14 edited
    What changed in the outcomes
    • EditedPharmacokinetics(PK) parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
    • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
    • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
    • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
    • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
    • EditedPK parameters(phase IIa/IIIb)Time frame: up to 12 weeks → up to 20weeks
    • EditedDisease Control Rate(DCR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
    • Edited(Clinical Benefit Rate(CBR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
    • EditedDuration of Response(DOR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
    • EditedTime to Response(TTR)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
    • EditedProgression Free Survival(PFS)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
    • EditedOverall Survival(OS)(phase IIa/IIIb)Time frame: Through study completion, an average of 3 years
    • EditedObjective Response Rate(ORR)(phase IIa)Time frame: from first dose to phase I completion, an average of 1.5 years → from first dose to phase Ia completion
    • ChangedBefore the incidence and severity of adverse events, serious adverse events, deaths, and safety screening abnormalities(phase I/II)Now Other safety endpoints(phase Ia/Ib)Time frame: From enrollment up to 30 days after last dose
    Interventions Added Drug: XS-02 capsules; removed XS-02 capsules. Arm changed Phase I dose escalation/Phase II dose expansion→Phase I dose escalation and dose expansion
    Sponsor NovaOnco Therapeutics Co., Ltd.→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    Design Removed Phase 2
    Title A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06531486
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Aug 15, 2024
Primary completion
May 15, 2029 (estimated)
Completion
Nov 13, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Lingying Wu
Contact
wulingying@csco.org.cn
+86 010-87788996

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion